Form 4 for EW Edwards Lifesciences
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-09 · accession 0001225208-26-000558 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-09 | 2026-01-09 | EW | Lippis Daniel J. | CVP, TAVR | S - Sale+OE | $85.70 | -1,019 | 22.0K | -4% | -$87.3K |
| D | 2026-01-09 | 2026-01-09 | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $59.26 | +1,019 | 23.0K | +5% | +$60.4K |
| D | 2026-01-09 | 2026-01-09 | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $0.00 | -1,019 | 4,076 | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-09 | S | D | 1,019 | $85.70 | 22,001.91 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2026-01-09 | M | A | 1,019 | $59.26 | 23,020.91 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2026-01-09 | M | D | 1,019 | $0.00 | 4,076 | D | $59.26 · 2020-05-08 to 2026-05-07 | 1,019 Common Stock |